Simioli Francesca, Annunziata Anna, Lanza Maurizia, Cardone Maria, Coppola Antonietta, Marotta Antonella, Calabrese Cecilia, Fiorentino Giuseppe
Department of Respiratory Pathophysiology and Rehabilitation, Azienda Ospedaliera di Rilievo Nazionale dei Colli, Monaldi Hospital, Naples, Italy.
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Azienda Ospedaliera di Rilievo Nazionale dei Colli, Monaldi Hospital, Naples, Italy.
Respiration. 2025;104(8):549-555. doi: 10.1159/000545165. Epub 2025 Mar 28.
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease that subverts the normal structure of the lungs and finally causes respiratory failure. High-flow nasal therapy (HFNT) is currently used in the acute setting for IPF with acute respiratory failure. Also, acute exacerbation of IPF and end-stage disease are common indications. Chronic cough is often an unmet need in IPF because it is partially responsive to common pharmacological treatment. Moreover, opioids have known adverse events. The aim of this paper was to investigate the effects and safety of chronic HFNT on lung function and symptoms of IPF.
This is a single-center case-control study including patients affected by IPF. We included 35 adult patients with a consistent radiological diagnosis of IPF, clinical history of lung function decline, and high prevalence of symptoms. All patients received the standard of treatment, particularly including antifibrotic drugs and conventional oxygen therapy (COT). Eighteen subjects were assigned to additional treatment with HFNT for 12 months.
No significant differences were observed after the follow-up with HFNT in terms of lung function. The mean forced vital capacity (FVC) was 1.89 ± 0.73 L with HFNT and 2.43 ± 0.87 L without HFNT (p = 0.09). The mean FVC decline per year was 190 mL with HFNT versus 200 mL with standard of care. The mean DLCO % of predicted was 28.86 ± 14.51% with HFNT and 36.03 ± 19.18% with COT (p = 0.276). No significant impact was observed on dyspnea; the mean Borg scale value was 6.72 ± 2.22 after HFNT and 7.14 with COT (p = 0.56). The score for cough significantly improved after treatment with a mean score in the HFNT group being 46.67 ± 10.85 versus 73.8 ± 18.43 (p < 0.0001) with standard of care.
Long-term HFNT significantly reduces chronic cough in patients affected by IPF compared to COT. Lung function including FVC and DLCO is not significatively influenced.
特发性肺纤维化(IPF)是一种慢性进行性疾病,会破坏肺部的正常结构,最终导致呼吸衰竭。高流量鼻导管治疗(HFNT)目前用于急性呼吸衰竭的IPF急性发作期。此外,IPF急性加重期和终末期疾病也是常见的适应症。慢性咳嗽在IPF中往往是一个未得到满足的需求,因为它对常见的药物治疗部分有效。此外,阿片类药物存在已知的不良事件。本文的目的是研究慢性HFNT对IPF患者肺功能和症状的影响及安全性。
这是一项单中心病例对照研究,纳入了IPF患者。我们纳入了35例成年患者,他们有一致的IPF放射学诊断、肺功能下降的临床病史且症状发生率高。所有患者均接受标准治疗,特别是包括抗纤维化药物和常规氧疗(COT)。18名受试者被分配接受额外的HFNT治疗12个月。
HFNT随访后,肺功能方面未观察到显著差异。接受HFNT治疗时平均用力肺活量(FVC)为1.89±0.73L,未接受HFNT治疗时为2.43±0.87L(p=0.09)。HFNT组每年FVC平均下降190mL,而标准治疗组为200mL。HFNT组预计的平均一氧化碳弥散量(DLCO)%为28.86±14.51%,COT组为36.03±19.18%(p=0.276)。未观察到对呼吸困难有显著影响;HFNT治疗后平均Borg量表值为6.72±2.22,COT治疗后为7.14(p=0.56)。治疗后咳嗽评分显著改善,HFNT组平均评分为46.67±10.85,而标准治疗组为73.8±18.43(p<0.0001)。
与COT相比,长期HFNT可显著减轻IPF患者的慢性咳嗽。包括FVC和DLCO在内的肺功能未受到显著影响。